Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of drug development, announced it has raised an additional $11 million in funding, bringing its total raised to $17.5 million. The new financing was led by The Aligned Fund, with participation from Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive Capital, and others..

Dash Bio是一家重塑药物开发速度和规模的临床前和临床生物分析公司，宣布其已获得额外1100万美元的融资，使其总融资额达到1750万美元。新一轮融资由The Aligned Fund领投，Freestyle Capital、Cybernetix Ventures、Swift Ventures、LifeX Ventures、Drive Capital等参与投资。